Hematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus
Authors:
- Luiz Guilherme Darrigo JuniorLJLuiz Guilherme Darrigo Junior
- Ana Karine VieiraAVAna Karine Vieira
- Cilmara KuwaharaCKCilmara Kuwahara
- Roseane Vasconcelos GouveiaRGRoseane Vasconcelos Gouveia
- Paulo KlingerPKPaulo Klinger
- Alexandre de Albuquerque AntunesAAAlexandre de Albuquerque Antunes
- Julia Lopes GarciaJGJulia Lopes Garcia
Open Access
- 22 January 2025
- journal article
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Abstract
Allogeneic hematopoietic cell transplantation (HCT) represents a critical therapeutic option for patients with transfusiondependent thalassemia (TDT), with thalassemia-free survival rates exceeding 90% in cases involving HLA-matched sibling donors. Due to the limited availability of matched donors, alternative sources such as HLA-matched unrelated donors, haploidentical donors, and umbilical cord blood have broadened HCT eligibility. Despite its potential for cure, HCT involves risks like graft-versus-host disease, graft rejection, and transplant-related mortality. Recent improvements in conditioning regimens have enhanced patient outcomes and quality of life. Factors affecting HCT success in TDT include recipient age, disease complications, effective chelation therapy, Pesaro score, and donor compatibility. This article aimed to update the Brazilian consensus established by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, incorporating the latest advances in treating and managing TDT patients undergoing transplantation.Keywords
This publication has 31 references indexed in Scilit:
- Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Transfusion-Dependent Thalassemia: A Systematic Review and Meta-AnalysisTransplantation and Cellular Therapy, 2024
- Impact of iron overload in hematopoietic stem cell transplantationTransplant Immunology, 2023
- Hematopoietic Stem Cell Transplantation in ThalassemiaHematology/Oncology Clinics of North America, 2023
- Immunosuppression Boost With Mycophenolate Mofetil for Mixed Chimerism in Thalassemia TransplantsTransplantation and Cellular Therapy, 2022
- Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South IndiaTransplantation and Cellular Therapy, 2020
- Hematopoietic Stem Cell Transplantation for Severe Thalassemia Patients from Haploidentical Donors Using a Novel Conditioning RegimenTransplantation and Cellular Therapy, 2020
- Hematopoietic Stem Cell Transplantation in ThalassemiaHematology/Oncology Clinics of North America, 2018
- Outcomes of Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation by Using a Standard Myeloablative versus a Novel Reduced-Toxicity Conditioning Regimen According to a New Risk StratificationTransplantation and Cellular Therapy, 2014
- A New Stratification Strategy That Identifies a Subset of Class III Patients with an Adverse Prognosis among Children with β Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2007
- MARROW TRANSPLANTATION FOR THALASSAEMIAThe Lancet, 1982